Seattle Genetics (SGEN) PT Raised to $90 at RBC Capital; KEYNOTE-204 Delay Removes Overhang
Tweet
Share
E-mail
Get Alerts SGEN Hot Sheet
Price: $228.74 --0%
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
RBC Capital analyst Kennen MacKay raised the price target on Seattle Genetics (NASDAQ: SGEN) to $90.00 (from $89.00) while maintaining a Outperform rating.
- KEYNOTE-204's lengthy delay removing a near-term competitive catalyst and major overhang on the stock
- now see Adcetris positioned well for the long term in rrHL
- see focus now shifting to Q1 Adcetris sales, where we like the setup for a beat into the full quarter of 1L PTCL sal
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Moderna (MRNA) to Neutral
- Morgan Stanley Upgrades Suncor Energy (SU) to Overweight
- Viking Holdings (VIK) PT Raised to $121 at UBS Ahead of Q2 Earnings
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, FDA, Hot CommentsRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
